Results of the linear regression analyses to assess the association between BMI category and DAS28 at the final visit before stopping TNFi
| Adjusted HR (95% CI) | P value | Crude HR (95% CI) | P value | Mean (SD) DAS28 before stopping TNFi | |
|---|---|---|---|---|---|
| All TNFi | |||||
| BMI category | |||||
| Underweight | −0.25 (−0.51; 0.0091) | 0.059 | −0.27 (−0.55; −0.00017) | 0.050 | 3.4 (1.5) |
| Normal weight | Ref | Ref | 3.8 (1.6) | ||
| Pre-obesity | 0.092 (−0.024; 0.21) | 0.120 | 0.076 (−0.042; 0.19) | 0.207 | 3.9 (1.6) |
| Obesity class I | 0.13 (−0.028; 0.29) | 0.106 | 0.20 (0.039; 0.36) | 0.015 | 4.1 (1.6) |
| Obesity class II | 0.31 (0.039; 0.59) | 0.025 | 0.38 (0.098; 0.67) | 0.009 | 4.2 (1.6) |
| Obesity class III | 0.45 (0.039; 0.87) | 0.032 | 0.65 (0.22; 1.08) | 0.003 | 4.6 (1.7) |
Mean (SD) DAS based on non-imputed data. Median (IQR) time between the final available DAS28 and stopping treatment with the TNFi was 0.9 (0.0; 5.2) months.
Linear regression analyses are based on multiply imputed data. Adjusted analyses were corrected for gender, smoking, age, baseline DAS28 and GC use.
BMI, body mass index; DAS, disease activity score; GC, glucocorticoid; TNFi, tumour necrosis factor inhibitor.